A multicenter, prospective, randomized, open-label, controlled trial to evaluate the efficacy
and safety of genotype-guided targeted agents plus cyclophosphamide, doxorubicin,
vincristine, and prednisone (CHOP-X2) versus cyclophosphamide, doxorubicin, vincristine, and
prednisone (CHOP) in patients with peripheral T-cell lymphoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Ruijin Hospital
Collaborators:
Nanfang Hospital of Southern Medical University Peking University People's Hospital Sun Yat-sen University Tongji Hospital West China Hospital